Rehabilitation Using Mobile Health for Older Adults With Ischemic Heart Disease in the Home Setting (RESILIENT): Protocol for a Randomized Controlled Trial

Abstract

Background Participation in ambulatory cardiac rehabilitation remains low, especially among older adults. Although mobile health cardiac rehabilitation (mHealth-CR) provides a novel opportunity to deliver care, age-specific impairments may limit older adults’ uptake, and efficacy data are currently lacking. Objective This study aims to describe the design of the rehabilitation using mobile health for older adults with ischemic heart disease in the home setting (RESILIENT) trial. Methods RESILIENT is a multicenter randomized clinical trial that is enrolling patients aged ≥65 years with ischemic heart disease in a 3:1 ratio to either an intervention (mHealth-CR) or control (usual care) arm, with a target sample size of 400 participants. mHealth-CR consists of a commercially available mobile health software platform coupled with weekly exercise therapist sessions to review progress and set new activity goals. The primary outcome is a change in functional mobility (6-minute walk distance), which is measured at baseline and 3 months. Secondary outcomes are health status, goal attainment, hospital readmission, and mortality. Among intervention participants, engagement with the mHealth-CR platform will be analyzed to understand the characteristics that determine different patterns of use (eg, persistent high engagement and declining engagement). Results As of December 2021, the RESILIENT trial had enrolled 116 participants. Enrollment is projected to continue until October 2023. The trial results are expected to be reported in 2024. Conclusions The RESILIENT trial will generate important evidence about the efficacy of mHealth-CR among older adults in multiple domains and characteristics that determine the sustained use of mHealth-CR. These findings will help design future precision medicine approaches to mobile health implementation in older adults. This knowledge is especially important in light of the COVID-19 pandemic that has shifted much of health care to a remote, internet-based setting. Trial Registration ClinicalTrials.gov NCT03978130; https://clinicaltrials.gov/ct2/show/NCT03978130 International Registered Report Identifier (IRRID) DERR1-10.2196/32163

Cardiac rehabilitation for heart failure: progress and gaps in evidence and policy

“…Participants are assigned to either traditional cardiac rehabilitation alone or the intervention arm. This intervention combines using mobile health software (mHealth-CR) with weekly therapist sessions to monitor progress [17,18 ▪ ].…”

Goal setting among older adults starting mobile health cardiac rehabilitation in the RESILIENT trial

“…The RESILIENT trial (NCT03978130) aims to evaluate whether mHealth-CR improves functional capacity (primary outcome) in older adults (age ≥65) with IHD compared with usual care. 6 Participants are identified at the time of acute myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft. This study randomized 400 patients in a 3:1 manner to mHealth-CR versus usual care.…”

Cardio-Oncology: Managing Cardiovascular Complications of Cancer Therapies

“…Likewise, variations in genes linked to cardiovascular function and systems for repairing damage can influence the likelihood of developing cardiotoxicity. Comprehending the genetic factors that cause heart toxicity shows potential for personalized healthcare, enabling the detection of patients with greater susceptibility and creating customized treatments [ 39 ]. Genetic testing has the potential to become a crucial part of assessing risk levels, allowing healthcare professionals to enhance cancer treatment plans while reducing the likelihood of cardiovascular issues [ 40 ].…”

“…Implementing cardio-oncology clinics, patient education, and support programs additionally augment the standard of care. Promising advancements in research and future medicines are expected to enhance the field and results for cancer patients susceptible to cardiovascular problems [ 39 ]. Continuing clinical trials and research endeavors will further influence the developing field of cardio-oncology, ultimately resulting in more tailored and efficient care methods [ 44 ].…”